Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) EPS (Weighted Average and Diluted) (2022 - 2026)

Axsome Therapeutics' EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$1.26 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 3.28% to -$1.26 in Q1 2026 year-over-year; TTM through Mar 2026 was -$3.72, a 35.53% increase, with the full-year FY2025 number at -$3.68, up 38.56% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$1.26 in Q1 2026 for Axsome Therapeutics, down from -$0.55 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for AXSM hit a ceiling of -$0.26 in Q1 2023 and a floor of -$2.13 in Q4 2023.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$1.22 across 5 years, with a median of -$1.26 in 2026.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 75.47% in 2023 and later tumbled 453.85% in 2024.
  • Tracing AXSM's EPS (Weighted Average and Diluted) over 5 years: stood at -$1.43 in 2022, then crashed by 48.95% to -$2.13 in 2023, then grew by 27.7% to -$1.54 in 2024, then surged by 64.29% to -$0.55 in 2025, then tumbled by 129.09% to -$1.26 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for AXSM at -$1.26 in Q1 2026, -$0.55 in Q4 2025, and -$0.94 in Q3 2025.